The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
(2022) Cancers — Vol. 14, n° 7, p. 1640 (2022)
Files
cancers-14-01640.pdf
Open Access - Adobe PDF
- 1.79 MB
Details
- Authors
- Abstract
- <jats:p>Urothelial carcinoma is an aggressive cancer and development of metastases remains a challenge for clinicians. Immune checkpoint inhibitors (ICIs) are significantly improving the outcomes of patients with metastatic urothelial cancer (mUC). These agents were first used in monotherapy after failure of platinum-based chemotherapy, but different strategies explored the optimal use of ICIs in a first-line metastatic setting. The “maintenance” strategy consists of the introduction of ICIs in patients who experienced benefit from first-line chemotherapy in a metastatic setting. This allows an earlier use of ICIs, without waiting for disease progression. We review the optimal management of mUC in the era of ICIs, based on the key clinical messages arising from the pivotal trials.</jats:p>
- Affiliations
Centre Hospitalier de Jolimont, Rue Ferrer 159, 7100 Haine Saint Paul, Belgium Department of Medical Oncology
Citations
Houssiau, H., & Seront, E. (2022). The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Cancers, 14(7), 1640. https://doi.org/10.3390/cancers14071640 (Original work published 2022)